FindTrial
Sign In

Study on Cyclosporine Eye Drops for Treating Eye Surface Damage in Glaucoma Patients on Long-Term Treatment

EFFICACY OF TOPICAL CYCLOSPORINE 0.05% IN THE MANAGEMENT OF OCULAR SURFACE DISEASE IN PATIENTS ON LONG-TERM ANTIGLAUCOMA THERAPY: A PROSPECTIVE STUDY - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/05/110063
Enrollment
60
Registered
2026-05-05
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H401- Open-angle glaucoma

Interventions

Intervention1: Topical Cyclosporine A 0.05% Eye Drops: Topical cyclosporine A 0.05% ophthalmic emulsion will be administered twice daily in both eyes for a duration of 6 months in patients with ocular

Sponsors

Nethradhama Super Speciality Eye Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Diagnosed cases of glaucoma or ocular hypertension On topical antiglaucoma medications for 6 months or more Ability to provide informed consent

Exclusion criteria

Exclusion criteria: Active ocular infection or inflammation History of ocular surgery within the last 3 months Severe corneal pathology Contact lens wearers Hypersensitivity to cyclosporine Patients with autoimmune ocular surface disease unrelated to glaucoma therapy

Design outcomes

Primary

MeasureTime frame
Improvement in Non-Invasive Tear Break-Up Time Change in Tear Meniscus HeightTimepoint: 1 month, 3 months, and 6 months—

Secondary

MeasureTime frame
Reduction in Ocular Surface Staining ScoresTimepoint: 1 month, 3 months, and 6 months—

Countries

India

Contacts

Public ContactDr SAMPRITHA MALLIKARJUNAPPA

Nethradhama Super Speciality Eye Hospital

sampritha96@gmail.com9845875393

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 11, 2026